Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Girish N. Nadkarni"'
Autor:
GIRISH N. NADKARNI, DIPTI TAKALE, BRUCE NEAL, KENNETH W. MAHAFFEY, YSHAI YAVIN, MICHAEL K. HANSEN, FERGUS FLEMING, HIDDO L. HEERSPINK, STEVEN COCA
Publikováno v:
Diabetes. 71
Individuals with diabetic kidney disease (DKD) are at risk for progression, heart failure, and death. We assessed the association of KidneyIntelX, a bioprognostictest validated for DKD progression, with a composite time-to-event endpoint of 57% eGFR
Autor:
Michael K. Hansen, Steven G. Coca, Hiddo L. Heerspink, Kenneth W. Mahaffey, David Lam, Bruce Neal, Norm Rosenthal, Girish N. Nadkarni
Publikováno v:
Diabetes. 70
KidneyIntelX is a composite risk score incorporating biomarkers and clinical variables for predicting progression of prevalent diabetic kidney disease (DKD). The change of this score over time in response to SGLT2 inhibitors and how these changes ass
Autor:
Lili Chan, Girish N. Nadkarni, Barbara Murphy, Scott M. Damrauer, Fergus Fleming, Fadi Salem, Steven G. Coca, Michael J. Donovan
Publikováno v:
Diabetes. 69
The ability to predict rapid kidney function decline (RKFD) in patients with early stages of type 2 diabetic kidney disease (T2DKD) can improve long-term health outcomes through earlier intervention. Our objective was to develop a robust risk score f